泊沙康唑
伏立康唑
氟康唑
曲菌病
肺曲菌病
医学
重症监护医学
抗真菌
内科学
免疫学
皮肤病科
作者
Andrés F. Henao‐Martínez,Daniel B Chastain,George R. Thompson
摘要
Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), there is limited knowledge of real-world treatment pathways and medication switches. We queried the TrinetX global research network database and identified 5,410 patients diagnosed with IPA. The most common initial treatments were voriconazole (49%), fluconazole (11%), and posaconazole (7%). Most patients remained on voriconazole (80%) or isavuconazole (78%) throughout the treatment duration. Switches were more frequent for those initially treated with fluconazole, echinocandins, or posaconazole.
科研通智能强力驱动
Strongly Powered by AbleSci AI